Format

Send to

Choose Destination
Future Oncol. 2009 Oct;5(8):1211-20. doi: 10.2217/fon.09.106.

Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.

Author information

1
Department of Medicine, Saint Agnes Hospital, 900 South Caton Avenue, Box 198, Baltimore, MD 21229, USA.

Abstract

Cancer cachexia is a complex syndrome, affecting up to 60% of the approximately 1.4 million patients diagnosed with cancer each year in the USA. This condition is characterized by progressive deterioration of a patient's nutritional status, weight loss, anorexia, diminished quality of life and increased mortality and morbidity. Current therapy with progestational, anti-inflammatory and anabolic agents is often ineffective and has a large number of undesirable effects. The newly developed nonsteroidal selective androgen receptor modulator Ostarine has demonstrated promising results in Phase I and II clinical trials, increasing total lean body mass, enhancing functional performance and decreasing total tissue percent fat. This selective androgen receptor modulator may have the ability to perform as a potent anabolic agent with minimal side effects on other organs (prostate and hair follicles), thus presenting a new strategy in managing cancer cachexia. However, more extensive data is required before its efficacy is confirmed.

PMID:
19852734
DOI:
10.2217/fon.09.106
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center